Our Company
PRODUCTS
- ROLVEDON™ (eflapegrastim-xnst)
Development Pipeline
Investor Relations
Medical Affairs
Careers
Contact Us

Site Map

Home
Site Map

Site Map

Our Company

Company Philosophy
Corporate Compliance
Management
Responsibility
Board of Directors

Products

ROLVEDON™ (eflapegrastim-xnst)

Development Pipeline

Pipeline
Poziotinib
Clinical trials
Glossary

Investor Relations

Press releases
Events and presentations
Corporate governance
Annual report and proxy information
Financial information
Stock information
Investor FAQs

Medical Affairs

Medical Affairs
Medical Information
Grants
Expanded Access Program

Careers

Contact Us

Our Company

Company Philosophy
Corporate Compliance
Management
Responsibility
Board of Directors

Products

ROLVEDON™ (eflapegrastim-xnst)

Development Pipeline

Pipeline
Poziotinib
Clinical Trials
Glossary

Investor Relations

Press Releases
Events and Presentations
Corporate Governance
Annual Report and Proxy Information
Financial Information
Stock Information
Investor FAQs

Medical Affairs

Medical Information
Expanded Access Program

Careers

Contact Us

This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.

ROLVEDON is a trademark of Spectrum Pharmaceuticals, Inc.
© 2023 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
PP-ALL-00-0054

Site Map
Privacy Policy
Terms of Use
Contact Us